Published Time：

Read the client of Shenzhen News Network, March 15, 2022 News (Reporter Dong Fei) On March 5, 2022, the "Expert Consensus on the Prevention and Treatment of Novel Coronavirus Pneumonia with Traditional Chinese Medicine" was officially launched online in the "Chinese Journal of Integrated Traditional and Western Medicine". Antiviral granules, etc., were included. Lizhu Antiviral Granules produced by Lizhu Group were successfully selected.

This expert consensus clarifies the possible mechanisms and optimal intervention time for the prevention and treatment of the epidemic with traditional Chinese medicine, uses the expert consensus method, comprehensively explains the advantages and value of traditional Chinese medicine in the prevention and treatment of COVID-19, guides clinical doctors to use traditional Chinese medicine safely and rationally, and is expected to provide guidance for the treatment of patients in foreign epidemic countries or regions with traditional Chinese medicine and the clinical use of drugs in the future domestic epidemic prevention and control under normal conditions.

Entrusted by the China Population Welfare Foundation, the Respiratory Disease Drug Research Professional Committee of the China Association of Traditional Chinese Medicine, together with the Respiratory Disease Professional Committee of the World Federation of Traditional Chinese Medicine Societies and the Chronic Airway Disease Professional Committee of the China Medical Education Association, with Professor Sun Zengtao, chairman of the Respiratory Disease Drug Research Professional Committee of the China Association of Traditional Chinese Medicine, and Professor Lin Jiangtao, and Professor Zhang Hongchun, chairman of the Pulmonary Disease Branch of the Chinese Society of Traditional Chinese Medicine, as the team leaders, jointly formulated the "Expert Consensus on the Prevention and Treatment of Novel Coronavirus Pneumonia with Traditional Chinese Medicine" with experts from both traditional Chinese and Western medicine.

The "Expert Consensus on the Prevention and Treatment of Novel Coronavirus Pneumonia with Traditional Chinese Medicine" recommends treatment with traditional Chinese medicine for COVID-19, divided into mild, ordinary, severe, and critically ill types, as well as recovery period and other symptomatic treatment drug recommendations. Among them, the expert consensus points out that for mild patients (clinical manifestations mainly include fever, sore throat, and fatigue), and ordinary patients (clinical manifestations mainly include fever, body aches, cough, sore throat, and shortness of breath), it is recommended to use antiviral granules and other traditional Chinese medicines.

It is recommended to use antiviral granules for mild and ordinary patients.

The National Joint Prevention and Control Mechanism's "Guiding Opinions on the Prevention and Treatment of Cluster Epidemics of Novel Coronavirus Pneumonia with Traditional Chinese Medicine" clearly points out that the principle of "forwarding the pass, sinking the center of gravity, early intervention, and full-process intervention" should be adhered to, and traditional Chinese medicine intervention should be implemented comprehensively for confirmed patients, asymptomatic patients, and key controlled personnel. More and more successful treatment cases have proved that traditional Chinese medicine intervention has achieved remarkable results and played an irreplaceable important role in the battle against the novel coronavirus pneumonia epidemic.

Recently, with the spread of the novel coronavirus epidemic, the effectiveness of traditional Chinese medicine treatment has been widely recognized in the industry. At present, many cities in China have successively stated that they will deeply integrate traditional Chinese medicine into the entire process of prevention and treatment of novel coronavirus pneumonia. Recently, Carrie Lam, Chief Executive of the Hong Kong Special Administrative Region, said that she is pleased to see that the therapeutic and preventive functions of traditional Chinese medicine have played an important role in the fight against the epidemic, and the SAR government will further give play to the advantages and role of traditional Chinese medicine in the entire process of epidemic prevention and control; the Qingdao Municipal Health Commission of Shandong Province recently introduced that the local area has given full play to the advantages and characteristics of traditional Chinese medicine treatment with good efficacy and few side effects, and the traditional Chinese medicine treatment rate has reached 100%; Yanbian Korean Autonomous Prefecture of Jilin Province has also deeply integrated traditional Chinese medicine into the entire process of prevention and control of the novel coronavirus pneumonia epidemic.

Under the current urgent development of the epidemic and the lack of high-quality research data, the China Association of Traditional Chinese Medicine, entrusted by the China Population Welfare Foundation, undertook the task, jointly with the Respiratory Disease Professional Committee of the World Federation of Traditional Chinese Medicine Societies and the Chronic Airway Disease Professional Committee of the China Medical Education Association, referring to the "Diagnosis and Treatment Plan for Novel Coronavirus Pneumonia (Seventh Edition)" and "Diagnosis and Treatment Plan for Novel Coronavirus Pneumonia (Eighth Edition)" issued by the National Health Commission and the National Administration of Traditional Chinese Medicine, sorted out and summarized the experience of clinical doctors and patients in this anti-epidemic drug use, combined with the clinical research results of some traditional Chinese medicines and the special approval of traditional Chinese medicines for the treatment of COVID-19 by the State Drug Administration, with Professor Sun Zengtao, director of Tianjin Institute of Respiratory Diseases and chairman of the Respiratory Disease Drug Research Professional Committee of the China Association of Traditional Chinese Medicine, Professor Lin Jiangtao, director of the Respiratory Department of the China-Japan Friendship Hospital and chairman of the Respiratory Disease Drug Research Professional Committee of the China Association of Traditional Chinese Medicine, and Professor Zhang Hongchun, director of the Cadre Health Care Office of the China-Japan Friendship Hospital and chairman of the Pulmonary Disease Branch of the Chinese Society of Traditional Chinese Medicine, as the team leaders, formulated the "Expert Consensus on the Prevention and Treatment of Novel Coronavirus Pneumonia with Traditional Chinese Medicine".

The consensus clarifies the possible mechanisms and optimal intervention time for the prevention and treatment of the epidemic with traditional Chinese medicine, uses the expert consensus method, comprehensively summarizes the advantages and value of traditional Chinese medicine in the prevention and treatment of COVID-19, and aims to guide clinical doctors to use traditional Chinese medicine safely and rationally, and is expected to provide guidance for the treatment of patients in foreign epidemic countries or regions with traditional Chinese medicine and the clinical use of drugs in the future domestic epidemic prevention and control under normal conditions.

Among them, the expert consensus points out that for mild patients (clinical manifestations mainly include fever, sore throat, and fatigue), and ordinary patients (clinical manifestations mainly include fever, body aches, cough, sore throat, and shortness of breath), it is recommended to use antiviral granules (oral liquid) and other traditional Chinese medicines. Lizhu Antiviral Granules has become the popular choice due to its famous origin and guaranteed efficacy.

Lizhu Antiviral Granules is a unique traditional Chinese medicine compound preparation from a famous family.

"Lizhu brand" antiviral granules are unique traditional Chinese medicine compound preparations for the treatment of upper respiratory tract infections and influenza, developed by Sichuan Guangda Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Lizhu Pharmaceutical Group Co., Ltd., based on classic prescriptions. "Lizhu brand" antiviral granules have a high effective dose, twice that of similar products, high retention of effective substance components, and guaranteed efficacy.

The prescription of "Lizhu brand" antiviral granules consists of Isatis root, Forsythia suspensa, Gypsum, Anemarrhena asphodeloides, Phragmites communis, Rehmannia glutinosa, Pogostemon cablin, Acorus calamus, and Curcuma longa, which is a modified version of the classic prescriptions "Baihu Decoction", "Changpu Yujin Decoction", and "Qingwen Baidu Drink". It mainly treats clearing heat and removing dampness, cooling blood and detoxifying. It is used for wind-heat colds, warm disease fever, and lung-heat syndrome, with symptoms such as fever, headache, cough, dry throat, sore throat, and red urine; upper respiratory tract infections and influenza, and mumps with the above symptoms.

"Lizhu brand" antiviral granules has won 5 provincial and ministerial science and technology awards, including the first prize of the Science and Technology Award of the Chinese Society of Traditional Chinese Medicine, the first prize of the China Science and Technology Innovation Award, and the first prize of the Invention and Entrepreneurship Award of the China Invention Association, as well as 4 patent awards, including the gold medal at the 48th Geneva International Invention Exhibition and the China Patent Excellence Award, and has been granted 16 invention patents. In 2021, it was selected into the "Top 10 List of Clinical Evidence-Based Evaluation Index of Traditional Chinese Medicine (Influenza)" of the 13th Healthy China Forum.

Since its listing in 2001, this product has shown definite clinical efficacy and good safety, and has been widely recognized by doctors and patients. It has been rated as a "national key new product", "Sichuan Province famous, excellent, special and new product", and "Chengdu City famous and excellent product". It is a unique dosage form product, a dual-cross product of OTC/prescription drugs, and a protected traditional Chinese medicine product (level 2), included in the 2019 National Medical Insurance Catalog.

Transferred from: Shenzhen News Network